{
    "clinical_study": {
        "@rank": "104120", 
        "arm_group": [
            {
                "arm_group_label": "Haporine-S", 
                "arm_group_type": "Experimental", 
                "description": "Moderate to severe dry patients administered with with Haporine-S"
            }, 
            {
                "arm_group_label": "Restasis, Cyclosporine 0.05%", 
                "arm_group_type": "Active Comparator", 
                "description": "Moderate to severe dry eye patients with Restasis(cyclosporine 0.05%)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine efficacy and safety of Haporine-S eye drop for the\n      patients with moderate to severe dry eye disease in a multicenter phase III clinical trial."
        }, 
        "brief_title": "Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dry Eye Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is to compare the efficacy and the safety of topical Haposine-S and Restasis\u00ae eye\n      drop 0.05% for the patients with moderate to severe dry eye disease in a multicenter,\n      investigator(assessor) blind, parallel design, non-inferiority phase III trial.\n\n      Primary outcome is the change of corneal staining score(Oxford scheme) at 12 weeks from\n      baseline."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, age 20 or over\n\n          -  Patients with moderate to severe dry eye(DEWS Level II or over)\n\n          -  Be informed of the nature of the study and will give written informed consent\n\n        Exclusion Criteria:\n\n          -  Being treated with steroidal eye drop or non-steroidal anti-inflammatory eye drop for\n             dry eye\n\n          -  Being treated with systemic steroid or immunosuppressive\n\n          -  History of eyeball surgical operation within 6 months\n\n          -  Wearing contact lenses during participation of the study\n\n          -  Pregnancy or breastfeeding\n\n          -  Use of cyclosporine eye drop within 2 weeks\n\n          -  Intraocular pressure(IOP)> 25 mmHg\n\n          -  History of punctal occlusion within 1 month or during participation of the study\n\n          -  Hypersensitivity to the investigational products or be suspicious to them\n\n          -  Patients whom the investigator considers inappropriate to participate in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01804361", 
            "org_study_id": "UMT-2012-DH-HS-01", 
            "secondary_id": "1360-8040-3073-4190"
        }, 
        "intervention": [
            {
                "arm_group_label": "Haporine-S", 
                "description": "1 or 2 drops twice a day at 12 hour interval for 12 weeks", 
                "intervention_name": "Haporine-S", 
                "intervention_type": "Drug", 
                "other_name": "Haporine-S"
            }, 
            {
                "arm_group_label": "Restasis, Cyclosporine 0.05%", 
                "description": "1 or 2 drops twice a day at 12 hour interval for 12 weeks", 
                "intervention_name": "Restasis (cyclosporine 0.05%)", 
                "intervention_type": "Drug", 
                "other_name": "Restasis (cyclosporine 0.05%)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Dry Eye Syndromes", 
        "lastchanged_date": "September 30, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Jong-Soo LEE, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "602-739"
                    }, 
                    "name": "Busan National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jong-Soo LEE, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hyo-Myung KIM, MD, PhD", 
                    "phone": "+82-2-920-5776"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "136-705"
                    }, 
                    "name": "Korea University Anam Hospital"
                }, 
                "investigator": {
                    "last_name": "Hyo-Myung KIM, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jong Suk SONG, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "152-703"
                    }, 
                    "name": "Korea University Guro Hospital"
                }, 
                "investigator": {
                    "last_name": "Jong Suk SONG, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Myoung-Joon KIM, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "investigator": {
                    "last_name": "Myoung-Joon KIM, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mee Kum KIM, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Mee Kum KIM, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Hyung Keun LEE, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-720"
                    }, 
                    "name": "Yonsei University Gangnam Severance Hospital"
                }, 
                "investigator": {
                    "last_name": "Hyung Keun LEE, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety Study of Haporine-S in Subjects With Moderate to Severe Dry Eye, A Multicenter, Investigator(Assessor)Blind, Parallel Design, Non-inferiority Phase III Trial", 
        "other_outcome": [
            {
                "description": "Adverse Event will be assessed for the whole study period(1 year).", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Serious Adverse Event will be assessed for the whole study period(1 year).", 
                "measure": "Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "overall_contact": {
            "last_name": "Hyo-Myung Kim, MD, PhD", 
            "phone": "+82-2-920-5776"
        }, 
        "overall_official": [
            {
                "affiliation": "Korea University Anam Hospital", 
                "last_name": "Hyo-Myung KIM, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korea University Guro Hospital", 
                "last_name": "Jong Suk SONG, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Yonsei University Gangnam Severance Hospital", 
                "last_name": "Hyung Keun LEE, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Busan National University Hospital", 
                "last_name": "Jong-Soo LEE, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Mee Kum KIM, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "Myoung-Joon KIM, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Corneal fluorescein staining will be assessed at 0 day(baseline), 4 weeks and 12 weeks.", 
            "measure": "Corneal staining", 
            "safety_issue": "No", 
            "time_frame": "up to 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01804361"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Ocular Surface Disease Index(OSID) will be assessed at 0 day, 4 weeks and 12 weeks.", 
                "measure": "Ocular Surface Disease Index(OSID)", 
                "safety_issue": "No", 
                "time_frame": "0 day, 4 weeks and 12 weeks"
            }, 
            {
                "description": "Tear Breakup Time(TBUT) will be assessed at 0 day(baseline), 4 weeks and 12 weeks.", 
                "measure": "Tear Breakup Time(TBUT)", 
                "safety_issue": "No", 
                "time_frame": "0 day, 4 weeks and 12 weeks"
            }, 
            {
                "description": "Schirmer score will be assessed at 0 day(baseline), 4 weeks and 12 weeks.", 
                "measure": "Schirmer score", 
                "safety_issue": "No", 
                "time_frame": "0 day, 4 weeks and 12 weeks"
            }, 
            {
                "description": "Drug compliance(conjunctival hyperemia and burning etc) will be assessed at 0 day(baseline), 4 weeks and 12 weeks.", 
                "measure": "Drug compliance", 
                "safety_issue": "No", 
                "time_frame": "0 day, 4 weeks and 12 weeks"
            }, 
            {
                "description": "Level on dry eye severity grading scheme of DEWS will be assessed at 0 day(baseline), 4 weeks and 12 weeks.", 
                "measure": "DEWS(Dry Eye WorkShop) level", 
                "safety_issue": "No", 
                "time_frame": "0 day, 4 weeks and 12 weeks"
            }
        ], 
        "source": "DH Bio Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "BTO Pharm Co Ltd", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "DH Bio Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}